Fig. 1: Sphk2-KO suppresses liver cancer development in HFHSD-fed mice. | Oncogenesis

Fig. 1: Sphk2-KO suppresses liver cancer development in HFHSD-fed mice.

From: Ablation of sphingosine kinase 2 suppresses fatty liver-associated hepatocellular carcinoma via downregulation of ceramide transfer protein

Fig. 1: Sphk2-KO suppresses liver cancer development in HFHSD-fed mice.

Wild-type (WT) and Sphk2 knockout (KO) mice were fed with a high-fat, high-sugar diet (HFHSD) for 46 weeks. A body weight (BW) gain, B Photos of WT and KO littermates showing different BW gain, C liver mass, D % of liver mass/BW, E epididymal white adipose tissue (eWAT) mass, F % of eWAT/BW, G plasma non-esterified fatty acids (NEFA), H plasma total cholesterol (TC) and I plasma triglyceride (TG). J Tumor incidence. 3 of 14 WT developed visible tumors and an additional 2 of 14 WT mice developed neoplastic lesions in the liver, while 0 of 14 KO mice developed neither liver tumors nor lesions. K Macroscopic images of visible liver tumor. L Microscopic images of the neoplastic lesion following H&E staining, scale bar = 200 µm. Data are expressed as mean ± SD. n = 14. *p < 0.05; **p < 0.01; ***p < 0.001; versus WT.

Back to article page